Oklahoma Representative Daniel Pae is praising President Donald Trump’s executive order aimed at speeding up federal approval pathways for psychedelic-assisted therapies used to treat mental health conditions and addiction.
The order directs the U.S. Food and Drug Administration to fast-track reviews of psychedelic therapies and expand research access for patients dealing with conditions such as depression and substance use disorders. It also broadens access to experimental treatments through programs such as the federal Right to Try Act.
“President Trump’s executive order marks a major step forward in addressing our nation’s mental health and addiction crises,” Pae said. “Emerging research shows these treatments could offer real hope for individuals who have exhausted traditional options.”
Pae has authored multiple measures in recent years focused on studying psychedelic treatments in Oklahoma.
Last year, he introduced House Bill 4293 to expand research opportunities and further evaluate the safety and effectiveness of psychedelic treatments for Oklahomans facing mental illness and addiction.
In 2024, he also passed House Bill 2107 in the House, creating a pilot program to study psilocybin-assisted therapy for certain mental health conditions. The measure was not heard in the Senate.
Supporters of psychedelic-assisted therapy point to growing research suggesting compounds such as psilocybin and lysergide may help treat conditions like treatment-resistant depression and substance use disorders when used in controlled clinical settings.
A 2025 study found that a single dose of lysergide combined with psychotherapy could reduce anxiety symptoms for up to a year.
